Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Clinical trial NCT03794349 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03794349
Sponsor: Children's Oncology Group
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

High Risk Neuroblastoma Recurrent Neuroblastoma Refractory Neuroblastoma

Start date: 2019-07-08
Primary completion: 2025-03-31
Enrollment: 94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.